Follow
Ashlee Clark
Ashlee Clark
Verified email at monash.edu
Title
Cited by
Cited by
Year
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ...
Science translational medicine 11 (478), eaau5758, 2019
2612019
Identification of metabolically distinct adipocyte progenitor cells in human adipose tissues
A Raajendiran, G Ooi, J Bayliss, PE O’Brien, RB Schittenhelm, AK Clark, ...
Cell reports 27 (5), 1528-1540. e7, 2019
1192019
Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy
MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, ...
European urology 74 (5), 562-572, 2018
982018
The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer
RJ Rebello, E Kusnadi, DP Cameron, HB Pearson, A Lesmana, JR Devlin, ...
Clinical Cancer Research 22 (22), 5539-5552, 2016
802016
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer
AK Clark, AV Taubenberger, RA Taylor, B Niranjan, ZY Chea, E Zotenko, ...
Biomaterials 34 (20), 4777-4785, 2013
762013
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, ...
Nature communications 12 (1), 5049, 2021
422021
A rare castration‐resistant progenitor cell population is highly enriched in Pten‐null prostate tumours
L Sackmann Sala, F Boutillon, G Menara, A De Goyon‐Pélard, ...
The Journal of pathology 243 (1), 51-64, 2017
332017
Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts
JCY Lo, AK Clark, N Ascui, M Frydenberg, GP Risbridger, RA Taylor, ...
Oncotarget 7 (30), 47650, 2016
232016
Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer
LH Porter, MG Lawrence, H Wang, AK Clark, A Bakshi, D Obinata, ...
The Prostate 79 (11), 1326-1337, 2019
202019
Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancer
LH Porter, A Bakshi, D Pook, A Clark, D Clouston, J Kourambas, ...
The Journal of pathology 254 (2), 121-134, 2021
162021
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019; 11
MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello
7
Early intervention exercise training does not delay prostate cancer progression in Pten−/− mice
RA Taylor, SG Farrelly, AK Clark, MJ Watt
The Prostate 80 (11), 906-914, 2020
62020
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med 11: eaau5758
MJ Watt, AK Clark, LA Selth, VR Haynes, N Lister, R Rebello, LH Porter, ...
62019
The future of patient-derived xenografts in prostate cancer research
MG Lawrence, RA Taylor, GB Cuffe, LS Ang, AK Clark, DL Goode, ...
Nature Reviews Urology 20 (6), 371-384, 2023
32023
Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer
M Alizadeh-Ghodsi, KL Owen, SL Townley, D Zanker, SPG Rollin, ...
Cancer Research Communications 2 (7), 706-724, 2022
32022
Mast cell interactions at tumour interface drive progression in human prostate cancer
G Risbridger, S Ellem, R Taylor, M Frydenberg, D Pook, J Pedersen, ...
Endocrine Abstracts 35, 2014
12014
Defining the challenges and opportunities for using patient‐derived models in prostate cancer research
WN Brennen, C Le Magnen, S Karkampouna, N Anselmino, N Bock, ...
The Prostate 84 (7), 623-635, 2024
2024
Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptors
S Keerthikumar, A Clark, H Wang, B Phipson, A Bakshi, A Ryan, ...
2024
Defining focal neuroendocrine differentiation as a transcriptionally distinct form of prostate cancer pathology characterized by the expression of androgen receptors
R Quezada Urban, S Keerthikumar, A Clark, H Wang, B Phipson, ...
bioRxiv, 2024.03. 17.585125, 2024
2024
Abstract PR006: PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer
A Huglo, S Hedwards, M Lawrence, R Rebello, A Clark, G Risbridger, ...
Cancer Research 83 (11_Supplement), PR006-PR006, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20